Stocks TelegraphStocks Telegraph
Stock Ideas

REGN Company Profile and Key Details

NASDAQ : REGN

Regeneron Pharmaceuticals

$766.63
-8.645-1.12%
At Close 4:00 PM
50.48
B-ESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Regeneron Pharmaceuticals, Inc. (REGN) stock declined over -1.12%, trading at $766.63 on NASDAQ, down from the previous close of $775.28. The stock opened at $776.57, fluctuating between $760.00 and $790.00 in the recent session.

Stock Snapshot

775.275
Prev. Close
79.18B
Market Cap
760
Day Low
18.12
P/E Ratio
42.32
EPS (TTM)
35.77
Cash Flow per Share
776.57
Open
103.28M
Number of Shares
790
Day High
93.97%
Free Float in %
243.65
Book Value
975.12K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 05, 2026777.83790.00760.00766.63974.72K
Feb 04, 2026765.80779.78765.21775.06951.72K
Feb 03, 2026745.53773.72742.74759.18767.21K
Feb 02, 2026732.92763.56731.51755.02692.59K
Jan 30, 2026753.96774.37735.61741.451.31M
Jan 29, 2026755.73755.73742.80749.44920.01K
Jan 28, 2026765.15766.99747.57751.13824.47K
Jan 27, 2026762.47776.25761.50771.25644.28K
Jan 26, 2026750.09767.30750.09762.65933.17K
Jan 23, 2026757.31762.00747.30753.55665.68K
Jan 22, 2026750.34765.00747.37755.51760.03K
Jan 21, 2026736.71750.00735.00749.33787.13K
Jan 20, 2026729.40737.87718.38733.78784.77K
Jan 16, 2026749.09749.09726.43733.041.68M
Jan 15, 2026754.85756.50737.00741.92865.52K
Jan 14, 2026760.58766.64753.01754.14668.78K
Jan 13, 2026765.16765.99743.94758.91946.39K
Jan 12, 2026810.00811.09765.08768.001.32M
Jan 09, 2026802.97821.11790.88796.55711.53K
Jan 08, 2026805.81816.99800.68801.011.05M

Contact Details

Tarrytown, NY 10591-6707

United States

https://www.regeneron.com914 847 7000

About Company

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Company Information

Employees15158
Beta0.39
Sales or Revenue$14.20B
5Y Sales Change%1.103%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

ARGX
-30.56-3.59%
argenx SE$820.31UTHR
-3.66-0.76%
United Therapeutics Corporation$478.93MDGL
-15.19-3.17%
Madrigal Pharmaceuticals, Inc.$463.42VRTX
-11.71-2.49%
Vertex Pharmaceuticals Incorporated$458.81ALNY
-20.72-5.89%
Alnylam Pharmaceuticals, Inc.$331.24KRTX
0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX
2.28+0.75%
Praxis Precision Medicines, Inc.$305.62KRYS
-1.49-0.55%
Krystal Biotech, Inc.$267.64SGEN
-0.16-0.07%
Seagen Inc.$228.74CDTX
00
Cidara Therapeutics, Inc.$221.38

Company Overview

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $766.63 USD, losing -$8.64 (-1.12%) from the previous close of $775.27. The stock is currently mid-range between its 52-week high and low $476.49 and $821.11. With a market capitalization of about $79.18 billion, Regeneron Pharmaceuticals, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 966.82 thousand shares, in line with its 52-week average. Headquartered in Tarrytown, NY, Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Leonard S. Schleifer, the company employs approximately 15,158 people and listed since April 02, 1991. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 1.02%, SMA50 1.11%, SMA200 23.13%). The stock’s 14-day RSI is 53.54 (neutral), while the ATR of 22.61 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -6.63% below its high and over 60.89% above its low. Average 10-day trading volume of 891.25 thousand shares is in line with the 3-month average of 942.74 thousand, indicating normal recent market interest.

Dividend & Fair Value

Regeneron Pharmaceuticals, Inc. last paid a dividend of 3.52 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.17 thousand. This means the shares are trading below this model’s fair value.

Shareholding & Insider Activity

Regeneron Pharmaceuticals, Inc. has 104.17 million shares outstanding. The public float is 97.89 million shares, elevated short interest at 2.34% of float. This equals 2.35 million shares. The short ratio is 2.36 days. Institutional investors hold 91.99% of the float. Insiders own 1.93%. YANCOPOULOS GEORGE holds 786.38 thousand shares, STAHL NEIL has 51.00 thousand shares and MURPHY ANDREW J has 48.31 thousand shares. Over the past six months, insider transactions show net selling. They sold 3.40 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Regeneron Pharmaceuticals generated $14.20B in revenue, or $123.39 per share. Gross margin was 93.07%, operating margin 28.10%, and net profit margin 31.07%. Returns are healthy, with ROA at 13.34% and ROE at 16.99%.
On valuation metrics, Regeneron Pharmaceuticals trades at a P/E of 17.67, P/S of 5.57 and P/B of 2.55. The current ratio is 4.77 and quick ratio is 4.22. Operationally, the company’s inventory turnover is 0.62 and cash conversion cycle is -342.06 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.09, supported by a cash flow-to-debt ratio of 1.41.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Regeneron Pharmaceuticals posted revenue of $14.20B, down slightly from $13.12B in the prior quarter. Gross profit was $13.22B (margin 93.07%). Operating income was $3.99B (margin 28.1%). Net income was$4.41B (EPS $40.90).
The company ended the quarter with $10.84B in cash and short-term investments, a total debt of $2.70B, and net debt of - $27.10M. Total assets were $33.08B, with equity of $25.97B. Financials further reflected stability, with operating cash flow of $4.59B, free cash flow of $3.67B, and capital expenditures of - $926.40M.

Frequently Asked Questions

What is the current Regeneron Pharmaceuticals, Inc. (REGN) stock price?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock price is $766.63 in the last trading session. During the trading session, REGN stock reached the peak price of $790.00 while $760.00 was the lowest point it dropped to. The percentage change in REGN stock occurred in the recent session was -1.12% while the dollar amount for the price change in REGN stock was - $8.65.
REGN's industry and sector of operation?
The NASDAQ listed REGN is part of Biotechnology industry that operates in the broader Healthcare sector. Regeneron Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of REGN?
Mr. Joseph J. LaRosa
Executive Vice President, Gen. Counsel & Sec.
Mr. Robert E. Landry Jr.
Executive Vice President of Fin. & Chief Financial Officer
Dr. Andrew J. Murphy Ph.D.
Executive Vice President of Research
Ms. Patrice Gilooly
Senior Vice President of Quality Assurance & Operations
Mr. Christopher R. Fenimore
Senior Vice President, Head of Accounting & Controller
Mr. Bob McCowan
Senior Vice President of IT & Chief Information Officer
Mr. Daniel P. Van Plew
Executive Vice President and GM of Industrial Operations & Product Supply
Mr. Gerald Underwood
Senior Vice President of Technical Operations
Dr. Leonard S. Schleifer M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. George D. Yancopoulos M.D., Ph.D.
Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
Ms. Marion E. McCourt
Executive Vice President of Commercial
How REGN did perform over past 52-week?
REGN's closing price is 60.89% higher than its 52-week low of $476.49 where as its distance from 52-week high of $821.11 is -6.63%.
How many employees does REGN have?
Number of REGN employees currently stands at 15,158.
Link for REGN official website?
Official Website of REGN is: https://www.regeneron.com
How do I contact REGN?
REGN could be contacted at phone 914 847 7000 and can also be accessed through its website. REGN operates from 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States.
How many shares of REGN are traded daily?
REGN stock volume for the day was 975.12K shares. The average number of REGN shares traded daily for last 3 months was 966.82K.
What is the market cap of REGN currently?
The market value of REGN currently stands at $79.18B with its latest stock price at $766.63 and 103.28M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph